SCHEMBL3396643

SCHEMBL3396643

c1ccc(Cc2ccc(C3CC3)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
CALM1 P0DP23 1/20 0.39
S1PR1 P21453 2/20 0.38
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
CTSL P07711 1/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
NR3C1 P04150 1/20 0.34
S1PR3 Q99500 1/20 0.34
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
IDH1 O75874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1106846 0.79 CALM1 (0.37) CALM1CTSLRAB9ASMN1; SMN2NPC1
SCHEMBL20163176 0.77 CALM1 (0.58) CALM1CTSLRAB9ASMN1; SMN2NPC1
SCHEMBL21984047 0.72 CHRM2 (0.45) S1PR1ACHERAB9ANPC1HPGD
SCHEMBL18294977 0.68 CALM1 (0.46) CALM1CTSLRAB9ASMN1; SMN2NPC1
SCHEMBL10910046 0.68 CALM1 (0.46) CALM1CTSLRAB9ASMN1; SMN2NPC1
SCHEMBL1680764 0.68 CYP2A6 (0.53) CALM1CTSLSMN1; SMN2IDH1
SCHEMBL4155853 0.68 CTSL (0.46) CALM1CTSLRAB9ASMN1; SMN2NPC1
SCHEMBL9338807 0.68 TDP1 (0.50) CALM1CTSLRAB9ASMN1; SMN2NPC1
SCHEMBL3180066 0.68 CHRM2 (0.47) CALM1CTSLRAB9ANPC1ALDH1A1
SCHEMBL27968343 0.68 TP53 (0.48) ADORA2AADORA1CALM1CTSLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245023-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2011-12-28 EP disclosed
US-8071797-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-12-06 US disclosed
EP-2245023-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2010-11-03 EP disclosed
WO-2009101022-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2009-08-20 WO disclosed
US-20090208449-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208449-A1 Heterocyclic antiviral compounds EIF2AK2, HCCS, RTF2 ADORA2A 2003/4885ADORA1 1809/4885CALM1 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.